Related Experiment Videos
Betablocker treatment in diabetes mellitus
1Department of Internal Medicine, St Franziskus Hospital in Cologne, Germany. peter.sawicki@t-online.de
Insights
Beta-blockers are underutilized in diabetes despite proven cardiovascular benefits. Review indicates beta1-selective agents are safe and effective for hypertensive diabetic patients, improving outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Hypertensive diabetic patients face high cardiovascular morbidity and mortality.
- Beta-blockers significantly reduce cardiovascular events in these patients, especially post-myocardial infarction.
- Despite benefits, beta-blockers are underprescribed in diabetic populations due to safety concerns.
Purpose of the Study:
- To evaluate the safety and efficacy of beta1-selective beta-blockers in diabetic patients.
- To determine if adverse metabolic effects, hypoglycemia risk, or nephroprotective differences justify reduced use.
- To assess the impact of beta-blocker underprescription on cardiovascular outcomes in diabetes.
Main Methods:
- Literature analysis of studies on beta-blocker use in diabetic patients.
- Assessment of metabolic effects, hypoglycemia risk, and nephroprotective properties of beta1-selective agents.
- Comparison of beta-blocker efficacy with other antihypertensives in diabetes.
Main Results:
- Beta1-selective beta-blockers show no significant adverse effects on glucose metabolism or hypoglycemia.
- These agents do not mask hypoglycemia symptoms in diabetic patients.
- Beta-blockers offer comparable nephroprotection to ACE inhibitors in diabetic nephropathy.
Conclusions:
- Underutilization of beta1-selective beta-blockers in diabetes is unwarranted.
- Increased prescription of these agents could reduce cardiovascular mortality in diabetic patients.
- Addressing fears of side effects is crucial for optimizing hypertension management in diabetes.
Objectives:
Betablockers have been convincingly shown to reduce total and cardiovascular morbidity and mortality of hypertensive diabetic patients. In diabetic patients, after myocardial infarction, these agents confer a twice as high protective effect when compared to non-diabetic patients. However, most paradoxically, betablocking agents are used less frequently in diabetes. Control of hypertension is insufficient in most of the diabetic patients, probably because a combination of antihypertensive agents including betablockers is frequently needed to sufficiently control blood pressure but is not used in these patients. The fear of betablocker-associated side effects in diabetes may be partly responsible for the frequent antihypertensive mono-therapy and the resulting poor quality of blood pressure control among diabetic patients.
Design:
We have performed an analysis of the literature to assess whether possible adverse metabolic effects, a higher risk of hypoglycaemia or less nephroprotective effects of beta1-selective betablocking agents could justify the reticence in prescribing these antihypertensive agents to diabetic patients.
Results:
A thorough review of the literature does not indicate that beta1-selective betablocking agents have important adverse effects on glucose metabolism, prolong hypoglycaemia or mask hypoglycaemic symptoms. In diabetic nephropathy, betablockers are as nephroprotective as angiotensin converting enzyme inhibitors.
Conclusions:
The unnecessary less frequent prescription of beta1-selective betablockers in diabetes mellitus may contribute to the higher cardiovascular mortality among these patients.